ECCO 2024

Are all JAKies the same?

The quest for predictive markers goes on...

S1P-Modulators from a safety perspective

Real-world data from a H2H-study on Vedolizumab vs. Tofacitinib in UC

Primary sclerosing cholangitis – lessons from a large PSC-IBD registry

Combination of different drug classes - risks and benefits

Treatment targets in 2024 - a silent revolution

Cell-based therapies: The end of the story or the bright future?

Finally here: controlled trials in surgery!

A spotlight on the PROFILE study

Mirikizumab in CD

IL-23 in UC

Ustekinumab first, anti-p19 second?

Next chapter in S1P- and JAK-inhibition

Obefazimod & IL23R-CAR-Tregs - new molecules in focus

Darvadstrocel for complex perianal fistulas and Crohn’s Disease

Mirikizumab in moderate to severe Crohn’s disease: overall assessment of the VIVID-1 trial

PIZZICATO - new JAKies for crohn's disease

Results of the phase II PIZZICATO (ritlecitinib & brepocitinib) in Crohn's disease

Mirikizumab in crohn's disease

VIVID 1: Comparison of mirikizumab with ustekinumab in Crohn’s disease

Mirikizumab vs Ustekinumab

Tregs - a treatment for the future?

Changing the PROFILE of how we treat CD

VIVID 1: Mirikizumab in Crohn's Disease

Mirikizumab bei Morbus Crohn

Mirikizumab vs Ustekinumab

Mirikizumab στη θεραπεία της μέτριας προς βαρειά NC: Συνολική ανάλυση μελέτης Vivid-1

PIZZICATO - neue JAKs für Morbus Crohn

Resultaten van de fase 2 PIZZICATO (ritlecitinib & brepocitinib) studie in ziekte van Crohn

VIVID 1- Comparação do Mirikizumab com o Ustecinumab na Doença de Crohn

VTX-002 in patients with moderate to severe UC

Long term outcome of Obefazimod in UC

Risankizumab & guselkumab in ulcerative colitis

Mirikizumab in anti-TNF failures with UC

VTX002 (S1P-modulator) & obefazimod in ulcerative colitis

The efficacy of biologics and small molecules in microscopic colitis – an ECCO Confer Cases study results

VTX002 (S1P-Modulator) & Obefazimod bei Colitis Ulcerosa

VTX-002 in pazienti con colite ulcerosa da moderata a grave

lange-termijns uitkomst van obefazimod in UC

Leki biologiczne i małocząsteczkowe w terapii mikroskopowych zapaleń jelit – wnioski z badania ECCO Confer Cases

Risankizumab & Guselkumab bei Colitis Ulcerosa

Still a long road ahead in standards of care in IBD – the results of an E-QUALITY survey

Therapy in transition

Comparability examination between SB17 and Ustekimumab originator

Therapie im Umbruch

Esame di comparabilità tra SP17 e ustekimumab originator

Marzenia a rzeczywistość – wyniki ankiety E-QUALITY na temat standardów opieki w IBD

PROFILE: Biomarkers not successfull for therapy prediction

Changing treatment paradigm in CD

Should we proactively treat CD-patients having small bowel lesions on capsules?

PROFILE: practice-changing results

Biomarker for biological loss of response in CD?

Allogenic mesenchymal stem cells for complex fistula in CD: End of the story?

Early intervention in Crohn´s disease therapy

Results from the PROFILE-trial

Faut-il traiter les patients avec les lesions de Crohn en videocapsules?

PROFILE: Biomarker nicht erfolgreich zur Prädiktion der Therapieantwort

Risultati dallo studio PROFILE

Cambiano i paradigmi di trattamento nelle malattie di crohn

Intervenção terapêutica precoce na doença de Crohn

Biomarker for biological loss of response in CD?

Injection de cellules souches mesenchimateuses allogéniques dans les fistules complexes de la maladie de Crohn: Fin de l'histoire?

Towards the proactive management of AS-UC responding to IB-steroids

Guselkumab & Golimumab have complementary effects when given together

Guselkumab & Golimumab ont des effets complémentaires lorqu'ils sont associés

Vers un traitement plus agressif de la colite aigüe grave cortico-sensible

HD-WLE with segmental reinspection is not inferior to HD-dye-based CE in detecting colorectal neoplasia in IBD

Therapy in transition

Use of CAR-Tregs in IBD: preclinical data

Immunohomeostasis by regulatory CAR-T cells!?

Personalized treatment in IBD: reality or hype?

Immunohomöstase durch regulatorische CAR-T-Zellen!?

gepersonaliseerde aanpak van IBD: realiteit of hype?

HD-WLE με επανεξέταση των τμημάτων δεν υπολείπεται της χρωμοενδοσκόπησης στην ανίχνευση νεοπλασίας στο παχύ έντερο στις ΙΦΝΕ

Therapie im Umbruch

Utilizzo di cellule CAR Tregs nelle MICI: dati preclinici

Randomised clinical trials finally coming to IBD surgery!

End of the Kono-S legend!

Colectomy and the natural history of PSC – lessons form a large PSC-IBD registry

No changes to surgical techniques for ileosecal disection in CD

Extended mesenterectomy is not superior to mesenteric sparing resection to prevent postoperative recurrence of CD

Implication of proctocolectomy in patients affected by UC

MIRACLE project: Avoidance of protective Ileostomy

MIRACLE-Projekt: Verzicht auf protektive Ileostomie

Implicazioni della proctocolectomia in pazienti affetti da colite ulcerosa

Η εκτεταμένη εκτομή του μεσεντερίου δεν υπερέχει της διατήρησής του για την πρόληψη της μετεγχειρητικής νόσου του Crohn

La fin de la legende du Kono-S!

Los ensayos clínicos aleatorizados llegan a la cirugía de las EII

Kolektomia a historia naturalna PSC – czy istnieje zależność?

Molecular healing, our next goal?

Cicatrización molecular: nuestro próximo objetivo?

Molecular effects of IL-23p19 blockade

Transcriptomic profiles in patients with UC receiving filgotinib

Molekulare Effekte der IL-23p19-Blockade

Análise do Transcriptoma em doentes com colite ulcerosa tratados com Filgotinib

Diet & Lifestyle: Keys for the management of IBD!

Diet & Lifestyle: Keys for the management of IBD!